Below you will find information from the register publication of inside information. The information has been provided by the organisation.
- Registration date 03 dec 2018 - 07:12
- Statutory name argenx SE
- Title argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia
Date last update: 23 January 2019